AstraZeneca spearheads lung cancer alliance aiming to boost survival rates - FiercePharma

AstraZeneca spearheads lung cancer alliance aiming to boost survival rates  FiercePharma

AstraZeneca wants to double the five-year lung cancer survival rate by 2025. That's an ambitious target for a disease that's the leading cause of cancer deaths in ...



Comments

Popular posts from this blog

Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic ...

Mechanism and clinical progression of solid tumors bone marrow metastasis

Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions